Candesartan Cilexetil 32 mg/Hydrochlorothiazide 25 mg in Unselected Patients with High or Very High Cardiovascular Risk: Efficacy, Safety, and Metabolic Impact

  • Peter Bramlage, Hartmut Buhck, Claudia Zemmrich
  • Clinical Drug Investigation, January 2014, Springer Science + Business Media
  • DOI: 10.1007/s40261-014-0169-2

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1007/s40261-014-0169-2

The following have contributed to this page: Peter Bramlage